Sichenzia Ross Ference LLP Represents Inmune Bio, Inc. in a $40.0 Million Registered Direct Offering
Press Release – New York, New York – July 16, 2021 – Sichenzia Ross Ference LLP announced today that it represented Inmune Bio, Inc. (Nasdaq: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in a registered direct offering of common stock at a purchase price of $22.00 per share with two institutional investor. The gross proceeds from the offering were $40.0 million.
A.G.P./Alliance Global Partners acted as sole placement agent for the offering.
The Sichenzia Ross Ference LLP team was led by partners Marc Ross, Thomas Rose and Barrett DiPaolo.
- Sichenzia Ross Ference LLP Represents Good Gaming, Inc. in $3.1 Million Private Placement Offering - November 18, 2021
- The Growing Risk of Website Accessibility Litigation and How to Protect Your Business Against It - November 18, 2021
- Sichenzia Ross Ference LLP Represents Boustead Securities, LLC as Underwriter to MAINZ BIOMED B.V. in $11.5 Million U.S. Initial Public Offering - November 10, 2021